Physician profile
Michael B Hogan
NPI 1982691531
$9,702.17
in general payments reported to CMS, 2019-2025
35 companies · $2,449 in 2025
The $2,449 reported for 2025 was more than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,976 · 2020: $1,408 · 2021: $431 · 2022: $1,259 · 2023: $1,026 · 2024: $1,153 · 2025: $2,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,100 · Long Term Medical Supply Or Device Loan: $1,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,100.38 |
| Long Term Medical Supply Or Device Loan | $1,527.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $1,628.57 | 2019-2025 | Puraply, Affinity |
| Angiodynamics, INC. | $1,527.78 | 2025 | Auryon Laser System 100-120 Vac |
| Silk Road Medical, INC. | $1,509.12 | 2019-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Bard Peripheral Vascular, INC. | $1,459.99 | 2019-2025 | Rotarexs 6 F X 135 Cm |
| Endologix LLC | $1,223.54 | 2019-2025 | Alto Abdominal Stent Graft System, Afx2 Bifurcated Endograft System, Endocross Device |
| Penumbra, INC. | $449.45 | 2021-2025 | Penumbra System, Indigo System |
| W. L. Gore & Associates, INC. | $304.32 | 2019-2025 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Philips North America LLC | $247.14 | 2019-2023 | |
| Veryan Medical Incorporated | $149.13 | 2022-2023 | Biomimics 3d Vascular Stent System |
| Janssen Pharmaceuticals, INC | $148.10 | 2019-2022 | |
| Polynovo North America LLC | $145.60 | 2024-2025 | Novosorb Btm |
| Boston Scientific Corporation | $134.92 | 2022-2025 | Enroute Transcarotid Neuroprotection System, General - Vascular Intervention, Varithena Administration Pack |
| Venclose INC. | $110.70 | 2020 | |
| Cardiovascular Systems INC. | $75.84 | 2019-2022 | |
| Medtronic, INC. | $71.34 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $55.38 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Terumo Medical Corporation | $51.44 | 2019 | |
| Smith+Nephew, INC. | $45.93 | 2021-2025 | Renasys Touch |
| Baxter Healthcare | $45.02 | 2020 | |
| Cagent Vascular INC | $28.86 | 2025 | Serrantor |
| Biom'Up France Sas | $26.74 | 2020 | |
| Lemaitre Vascular, INC. | $26.47 | 2022 | |
| Davol INC. | $25.56 | 2020 | |
| Abbott Laboratories | $24.72 | 2022 | |
| Reflow Medical INC | $22.43 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.37 | 2023 | |
| Medtronic Vascular, INC. | $22.22 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $20.08 | 2021 | |
| Dilon Technologies, INC. | $18.58 | 2025 | Hemoblast Bellows |
| Cardiva Medical, INC. | $17.79 | 2025 | Cardiva Vascade 6/7f Vcs |
| Stryker Corporation | $16.27 | 2025 | Limflow System |
| Vifor Pharma, INC. | $13.04 | 2022 | |
| Bioventus LLC | $12.46 | 2022 | |
| Biocompatibles, INC. | $11.62 | 2019 | |
| Medela LLC | $9.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.